Omalizumab biosimilar - Shanghai Zhangjiang Biotechnology

Drug Profile

Omalizumab biosimilar - Shanghai Zhangjiang Biotechnology

Alternative Names: Aomaishu; CMAB-007

Latest Information Update: 30 Dec 2015

Price : $50

At a glance

  • Originator Shanghai Zhangjiang Biotechnology
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Allergic asthma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Dec 2015 Shanghai Zhangjiang Biotechnology completes a phase II/III trial in Allergic asthma (In adolescents, In adults) in China (NCT01976208)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top